Merck’s Lipfendra became the first oral PCSK9 inhibitor to receive FDA approval, expanding the cholesterol-lowering class beyond injectable therapies. The approval positions Lipfendra as a macrocyclic peptide engineered for oral formulation, designed to deliver PCSK9 pathway inhibition without the injections that have characterized earlier PCSK9 therapies. For lipid management and cardiovascular prevention strategies, the decision affects both patient adherence dynamics and the competitive landscape across cardiometabolic portfolios. Market participants will now watch launch sequencing, formulary decisions, and comparative uptake versus established injectable PCSK9 inhibitors.